Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
暂无分享,去创建一个
S J Gange | S. Gange | J. Metcalf | J. Mellors | J. Coffin | E. Acosta | F. Maldarelli | S. Palmer | A. Wiegand | J M Coffin | M. Kearney | J A Metcalf | F Maldarelli | D McMahon | J Jones | A Wiegand | M Kearney | S Palmer | S McNulty | E Acosta | C Rehm | J W Mellors | Mary F. Kearney | D. McMahon | S. McNulty | C. Rehm | J. Jones | Steven G. McNulty | S. McNulty
[1] Hélène Jacqmin-Gadda,et al. Mixed models for longitudinal left-censored repeated measures , 2004, Comput. Methods Programs Biomed..
[2] I. Grant,et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.
[3] I. Pastan,et al. Anti‐HIV‐1 immunotoxin 3B3(Fv)‐PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques , 2006, Journal of leukocyte biology.
[4] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] N. Shaik,et al. P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution , 2007, Drug Metabolism and Disposition.
[6] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[7] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[8] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[9] L. Varatharajan,et al. The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research , 2009, Antiviral research.
[10] J. Wagner,et al. Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.
[11] C. Crumpacker,et al. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.
[12] M. Peeters,et al. Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood , 1995, Journal of medical virology.
[13] Yang Wang,et al. Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus , 2005, Journal of Virology.
[14] J. Hughes,et al. Mixed Effects Models with Censored Data with Application to HIV RNA Levels , 1999, Biometrics.
[15] W. Haefeli,et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. , 2007, Biochemical pharmacology.
[16] J. Mellors,et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. , 2009, The Journal of infectious diseases.
[17] D. Ho,et al. Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.
[18] I. Grant,et al. Low atazanavir concentrations in cerebrospinal fluid , 2009, AIDS.
[19] D. Hazuda,et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase , 2007, AIDS.
[20] John W. Mellors,et al. New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.
[21] J. Clements,et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: A model for human immunodeficiency virus patients on highly active antiretroviral therapy , 2005, Journal of NeuroVirology.
[22] Mario Clerici,et al. Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years , 2003, Journal of Virology.
[23] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[24] E. Acosta,et al. A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[25] T. Greenough,et al. Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy , 2009, Journal of Virology.
[26] D. Nickle,et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.
[27] A. Sher,et al. A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression. , 2001, The Journal of infectious diseases.
[28] Alan S. Perelson,et al. In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months , 2003, Journal of Virology.
[29] Lawrence Corey,et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. , 2007, The Journal of infectious diseases.
[30] L. Varatharajan,et al. Corrigendum to “The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research” [Antiviral Res. 82 (2) (2009) A99–A109] , 2009, Antiviral Research.
[31] R. Haubrich,et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. , 2008, The Journal of infectious diseases.
[32] S J Gange,et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.
[33] D. Hazuda,et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.
[34] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[35] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[36] Alan S Perelson,et al. Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication , 2004, Journal of acquired immune deficiency syndromes.
[37] Joseph A Kovacs,et al. ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.
[38] R. Siliciano,et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.
[39] C. Kovacs,et al. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.
[40] A. Trkola,et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.
[41] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[42] T. Chun,et al. Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.